Physiologic Study of Cerebral Perfusion

Phase 4

Completed

• Conditions: Cerebral Perfusion Pressure; Vasopressor Agents; Shock; Magnetic Resonance Imaging (MRI), Functional
• Interventions: Drug: Propofol for light sedation; Drug: Lower doses of vasopressor therapy for a MAP of 65 mmHg; Drug: Higher doses of vasopressor therapy for a MAP of 75 mmHg

• Registration Number: NCT02744625
• Lead Sponsor: Centre de recherche du Centre hospitalier universitaire de Sherbrooke

Brief Summary

The aim of the study is to measure cerebral perfusion using MRI in healthy subjects (with and without sedation) and in vasopressor-dependent patients

Detailed Description

Not available

Study Timeline

• Study Start: 2016-04
• Study First Submitted: 2016-04-07
• Study First Submitted QC: 2016-04-15
• Study First Posted: 2016-04-20
• Status Verified: 2017-03
• Primary Completion: 2017-03
• Study Completion: 2017-03
• Last Update Submitted: 2017-03-28
• Last Update Posted: 2017-03-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 22

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Healthy participant sedated	Propofol for light sedation	Healthy participant Under light sedation
Shock lower Mean Arterial Pressure (MAP)	Lower doses of vasopressor therapy for a MAP of 65 mmHg	Vasopressor-dependent treated to lower MAP (65 mmHg)
Shock higher MAP	Higher doses of vasopressor therapy for a MAP of 75 mmHg	Vasopressor-dependent treated to higher MAP (75 mmHg)
Shock lower Mean Arterial Pressure (MAP)	Propofol for light sedation	Vasopressor-dependent treated to lower MAP (65 mmHg)
Shock higher MAP	Propofol for light sedation	Vasopressor-dependent treated to higher MAP (75 mmHg)

Primary Outcome Measures

Name	Time	Method
Global and regional cerebral blood flow	Within 15 minutes of intervention initiation	Cerebral blood flow will be measured by the arterial spin labeling technique (ASL) which provides information expressed in mL/100g/min. Using 3-T MRI technology,we will first acquire T1 images of the brain and sub-regions of interest. Thereafter, ASL sequences will be acquired in contiguous slices. The procedure will be followed on sedation and off sedation for healthy volunteers (in random order) and at mean arterial pressure of 65 mmHg and 75 mmHg (in random order) in patients receiving vasopressor therapy.

Trial Locations

Locations (1)

Université de Sherbrooke; 🇨🇦 Sherbrooke, Quebec, Canada